---
type: claim
domain: health
description: "C-SNPs (chronic condition special needs plans) grew 71% 2024-2025 and now represent 16% of all SNP enrollment, signaling shift toward managed care for metabolic and chronic disease populations"
confidence: proven
source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
created: 2025-07-24
---

# Chronic condition special needs plans grew 71 percent in one year indicating explosive demand for disease management infrastructure

C-SNPs (Chronic Condition Special Needs Plans) grew 71% from 2024 to 2025, reaching 1.2 million enrollees and representing 16% of all Special Needs Plan enrollment. This is the fastest-growing segment of Medicare Advantage and signals a structural shift toward managed care models specifically designed for chronic disease populations.

The growth is occurring within the broader SNP expansion: SNPs overall grew from 14% of MA enrollment in 2020 to 21% in 2025 (7.3M enrollees). But C-SNPs are growing far faster than D-SNPs (dual-eligible) or I-SNPs (institutional), indicating that chronic disease management — not just Medicaid coordination or nursing home care — is the primary driver of specialized MA plan growth.

This connects directly to the metabolic disease epidemic and the GLP-1 therapeutic category launch. C-SNPs are purpose-built for populations with diabetes, heart failure, chronic kidney disease, and other conditions that require continuous monitoring, medication management, and care coordination. The 71% growth rate suggests these plans are capturing demand from beneficiaries who need more than standard MA plans provide but don't qualify for dual-eligible or institutional SNPs.

## Evidence

**C-SNP growth trajectory:**
- 2024-2025: 71% growth (fastest-growing MA segment)
- 2025 enrollment: 1.2M beneficiaries
- Share of SNP enrollment: 16%

**SNP overall growth:**
- 2020: 14% of MA enrollment
- 2025: 21% of MA enrollment (7.3M total)
- Growth concentrated in C-SNPs, not D-SNPs or I-SNPs

**SNP breakdown (2025):**
- D-SNPs (dual-eligible): 6.1M (83% of SNPs)
- C-SNPs (chronic conditions): 1.2M (16%)
- I-SNPs (institutional): 115K (2%)

**Why this matters:**

C-SNPs are designed for beneficiaries with specific chronic conditions (diabetes, heart failure, CKD, COPD, etc.) who need:
- Continuous monitoring (remote patient monitoring, wearables)
- Medication adherence programs
- Care coordination across specialists
- Disease-specific protocols

The 71% growth indicates:
1. **Chronic disease prevalence is accelerating** — More beneficiaries qualify for C-SNP enrollment
2. **Standard MA plans are insufficient** — Beneficiaries are actively seeking specialized chronic disease management
3. **Plans see ROI in disease management infrastructure** — 71% growth means plans are investing heavily in C-SNP capacity

This is the demand signal for GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md and for continuous monitoring infrastructure like Oura controls 80 percent of the smart ring market with patent-defended form factor while a demographic pivot from fitness enthusiasts to wellness-focused women drives 250 percent sales growth.md.

---

Relevant Notes:
- the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md
- Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md
- continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware.md

Topics:
- domains/health/_map
